APREA THERAPEUTICS INC (APRE) Stock News

USA - NASDAQ:APRE - US03836J2015 - Common Stock

1.27 USD

+0.04 (+3.25%)

Last: 11/10/2025, 8:00:00 PM

1.2308 USD

-0.04 (-3.09%)

After Hours: 11/10/2025, 8:00:00 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

APRE Latest News, Press Relases and Analysis

All

Press Releases

18 days ago - By: Aprea Therapeutics

Aprea Therapeutics Provides Clinical Update from ACESOT-1051 Trial Showing Early Signals of Activity for WEE1 Kinase Inhibitor APR-1051

18 days ago - By: Aprea Therapeutics

Aprea Therapeutics Provides Clinical Update from ACESOT-1051 Trial Showing Early Signals of Activity for WEE1 Kinase Inhibitor APR-1051

a month ago - By: Aprea Therapeutics

Aprea Therapeutics Establishes Recommended Phase 2 Dose (RP2D) for ATRN-119, Considering Combination Therapies

a month ago - By: Aprea Therapeutics

Aprea Therapeutics Announces Presentations at EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics

2 months ago - By: Benzinga - Mentions: CODX RNAZ ISPC QNRX ...

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

3 months ago - By: Aprea Therapeutics

Aprea Therapeutics to Present at H.C. Wainwright Global Investment Conference

3 months ago - By: Aprea Therapeutics

Aprea Therapeutics to Present at H.C. Wainwright Global Investment Conference

3 months ago - By: Aprea Therapeutics

Aprea Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Clinical Update

3 months ago - By: Aprea Therapeutics

Aprea Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Clinical Update

4 months ago - By: Benzinga - Mentions: CYH ABP CASI VKTX ...

12 Health Care Stocks Moving In Wednesday's After-Market Session

5 months ago - By: Aprea Therapeutics

Aprea Reports Anti-Proliferative Results and Promising Early-Stage Clinical Data for Next-Generation WEE1 Inhibitor, APR-1051, in HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) in Collaboration with MD Anderson Cancer Center

5 months ago - By: Aprea Therapeutics

Aprea Reports Anti-Proliferative Results and Promising Early-Stage Clinical Data for Next-Generation WEE1 Inhibitor, APR-1051, in HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) in Collaboration with MD Anderson Cancer Center

6 months ago - By: Aprea Therapeutics

Aprea Therapeutics Reports First Quarter 2025 Financial Results and Provides a Clinical Update

6 months ago - By: Aprea Therapeutics

Aprea Therapeutics Reports First Quarter 2025 Financial Results and Provides a Clinical Update

8 months ago - By: Aprea Therapeutics

Aprea Therapeutics Announces Dosing of Patient with HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) in Ongoing ACESOT-1051 Trial

8 months ago - By: Aprea Therapeutics

Aprea Therapeutics Announces Dosing of Patient with HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) in Ongoing ACESOT-1051 Trial

8 months ago - By: Aprea Therapeutics

Aprea Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update

8 months ago - By: Aprea Therapeutics

Aprea Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update

8 months ago - By: Aprea Therapeutics

Aprea Therapeutics Announces Agreement with MD Anderson Cancer Center to Explore APR-1051 as a Potential Treatment for Head and Neck Squamous Cell Carcinoma (HNSCC)

8 months ago - By: Aprea Therapeutics

Aprea Therapeutics Announces Agreement with MD Anderson Cancer Center to Explore APR-1051 as a Potential Treatment for Head and Neck Squamous Cell Carcinoma (HNSCC)

9 months ago - By: Aprea Therapeutics

Aprea Therapeutics Announces Strategic IP Portfolio Evolution in DNA Damage Response (DDR) Cancer Therapeutics

9 months ago - By: Aprea Therapeutics

Aprea Therapeutics Announces Strategic IP Portfolio Evolution in DNA Damage Response (DDR) Cancer Therapeutics

a year ago - By: Aprea Therapeutics

Aprea Therapeutics Announces Twice Daily (BID) Dosing of Patients in ABOYA-119 Clinical Trial of ATRN-119 to Potentially Optimize Clinical Outcomes and Strengthen Clinical Path Forward

a year ago - By: Aprea Therapeutics

Aprea Therapeutics Announces Twice Daily (BID) Dosing of Patients in ABOYA-119 Clinical Trial of ATRN-119 to Potentially Optimize Clinical Outcomes and Strengthen Clinical Path Forward

a year ago - By: Aprea Therapeutics

Aprea Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

a year ago - By: Aprea Therapeutics

Aprea Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

a year ago - By: Aprea Therapeutics

Aprea Therapeutics Presents Preliminary Findings on Oral WEE1 Inhibitor APR-1051 at EORTC-NCI-AACR International Conference on Molecular Targets and Therapeutics

a year ago - By: Aprea Therapeutics

Aprea Therapeutics Presents Preliminary Findings on Oral WEE1 Inhibitor APR-1051 at EORTC-NCI-AACR International Conference on Molecular Targets and Therapeutics

a year ago - By: Aprea Therapeutics

Aprea Therapeutics to Present at Maxim 2024 Healthcare Virtual Summit

a year ago - By: Aprea Therapeutics

Aprea Therapeutics to Present at Maxim 2024 Healthcare Virtual Summit

a year ago - By: Aprea Therapeutics

Aprea Therapeutics Announces Presentations at EORTC-NCI-AACR International Conference on Molecular Targets and Therapeutics

a year ago - By: Aprea Therapeutics

Aprea Therapeutics Announces Presentations at EORTC-NCI-AACR International Conference on Molecular Targets and Therapeutics

a year ago - By: Aprea Therapeutics

Aprea Therapeutics Engages Philippe Pultar, MD to Serve as Senior Medical Advisor and Lead WEE1 Clinical Development

a year ago - By: Aprea Therapeutics

Aprea Therapeutics Engages Philippe Pultar, MD to Serve as Senior Medical Advisor and Lead WEE1 Clinical Development

a year ago - By: Aprea Therapeutics

Aprea Therapeutics to Participate in the Lytham Partners Fall 2024 Investor Conference on October 1, 2024

a year ago - By: Virtual Investor Conferences - Mentions: NYSE ACST AEMD UNCY ...

Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing